866-997-4948(US-Canada Toll Free)

Insomnia - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Nov 2010

Category :

Therapeutic Area

No. of Pages : 50 Pages


GlobalData, the industry analysis specialist, has released its new report, Insomnia Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Insomnia market. The report identifies the key trends shaping and driving the global Insomnia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Insomnia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

GlobalData estimated the global insomnia market to be valued at $2.75 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of -3.2% over the next seven years to reach $2.12 billion by 2017. The decline will be mainly due to the patent expiry of many drugs. Barriers to the insomnia market are strong in terms of both pricing (generics and me-too compounds in the market) and volume, with issues such as the low treatment-seeking rate and a low diagnosis rate, amongst others

Scope

The report provides information on the key drivers and challenges of the Insomnia market. Its scope includes: 

  • Annualized global Insomnia market revenues data from 2001 to 2009, forecast for eight years to 2017. 
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Serotonin receptor antagonists, Melatonin receptor agonists, GABA receptor modulators, Orexin receptor antagonists, 5-HT2A and histamine receptor antagonists and Phosphoprotien modulators.
  • Analysis of the current and future competition in the global Insomnia market. Key market players covered are Bayer Healtcare Pharmaceuticals, Pfizer Inc, GlaxoSmithKline, Takeda Pharmaceuticals, Actelion Ltd., Eli Lilly and Company and Vanda Pharmaceuticals.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Insomnia therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global Insomnia market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Insomnia market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum best opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global Insomnia insomnia market landscape? Identify, understand and capitalize.
Table Of Content

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 Insomnia Therapeutics: Introduction 6
2.1 GlobalData Pipeline Report Guidance 7

3 Insomnia Therapeutics: Market Characterization 8
3.1 Insomnia Market Size 8
3.2 Insomnia Market Forecast and CAGR 9
3.3 Drivers and Barriers for the Insomnia Market 10
3.3.1 Drivers for the Insomnia Market 10
3.3.2 Barriers for the Insomnia Market 10
3.4 Opportunity and Unmet Need 11
3.5 Key Takeaway 12

4 Insomnia Market: Competitive Assessment 13
4.1 Overview 13
4.2 Strategic Competitor Assessment 13
4.3 Product Sales for Major Insomnia Products 14
4.4 Product Profile for the Major Marketed Products in the Insomnia Market 14
4.4.1 Ambien CR (zolpidem tartrate extended-release) 14
4.4.2 Lunesta 15
4.4.3 Paxil (Paroxetine) 16
4.5 Other Marketed Products for the Insomnia Market 17
4.5.1 Zolpimist (zolpidem oral spray) 17
4.5.2 Edluar (zolpidem sublingual tablets) 18
4.5.3 Circadin (prolonged release melatonin) 18
4.6 Key Takeaway 19

5 Insomnia Market: Pipeline Assessment 20
5.1 Overview 20
5.2 Strategic Pipeline Assessment 20
5.2.1 Technology Trends Analytic Framework 20
5.3 Insomnia Therapeutics Promising Drugs under Clinical Development 22
5.4 Molecule Profile for Promising Drugs under Clinical Development 23
5.4.1 Ciltyri (eplivanserin) 23
5.4.2 Almorexant 23
5.4.3 Silenor (doxepin hydrochloride) 24
5.4.4 Tasimelteon (VEC-162) 25
5.4.5 Esmirtazapine (ORG 50081) 25
5.4.6 Indiplon 26
5.5 Insomnia Therapeutics Market Clinical Pipeline by Mechanism of Action 27
5.6 Insomnia Pipeline Pipeline by Clinical Phases of Development 28
5.6.1 Insomnia Therapeutics Regulatory and Phase III Clinical Pipeline 28
5.6.2 Insomnia Therapeutics Phase II Clinical Pipeline 29
5.6.3 Insomnia Therapeutics Phase I Clinical Pipeline 30
5.6.4 Insomnia Therapeutics Preclinical Pipeline 30
5.6.5 Insomnia Therapeutics Discovery Pipeline 30
5.7 Discontinued / Suspended Drugs for Insomnia 31
5.8 Key Takeaway 32

6 Insomnia Market: Implications for Future Market Competition 33

7 Insomnia Market: Future Players in Insomnia Market 34
7.1 Introduction 34
7.2 GlaxoSmithKline 35
7.2.1 Overview 35
7.2.2 CNS Portfolio 35
7.2.3 Insomnia Product Portfolio 37
7.3 Sanofi Aventis 38
7.3.1 Overview 38
7.3.2 CNS Portfolio 38
7.3.3 Insomnia Product Portfolio 39
7.4 Somaxon Pharmaceuticals 40
7.4.1 Overview 40
7.4.2 CNS Portfolio 40
7.4.3 Insomnia Product Portfolio 40
7.5 Vanda Pharmaceuticals Inc. 41
7.5.1 Overview 41
7.5.2 CNS Portfolio 41
7.5.3 Insomnia Product Portfolio 41
7.6 Merck 42
7.6.1 Overview 42
7.6.2 CNS Portfolio 42
7.6.3 Insomnia Product Portfolio 42

8 Insomnia Market: Appendix 44
8.1 Definitions 44
8.2 Acronyms 44
8.3 Research Methodology 45
8.3.1 Coverage 45
8.3.2 Secondary Research 45
8.3.3 Forecasting 46
8.3.4 Primary Research 49
8.3.5 Expert Panel Validation 49
8.4 Contact Us 49
8.5 Disclaimer 49
8.6 Sources 50

List of Table


Table 1: Insomnia Therapeutics Market, Global, Revenue ($m), 20012009 9
Table 2: Insomnia Therapeutics Market, Global, Revenue Forecasts, 20092017 10
Table 3: Insomnia Therapeutics Market, Advantages and Disadvantages of Major Marketed Products, 2009 19
Table 4: Insomnia Therapeutics Market, Most Promising Drugs under Clinical Development, 2009 22
Table 5: Insomnia Therapeutics Regulatory Filing and Phase III Clinical Pipeline, 2009 28
Table 6: Insomnia Therapeutics Phase II Clinical Pipeline, 2009 29
Table 7: Insomnia Therapeutics Phase I Clinical Pipeline, 2009 30
Table 8: Insomnia Therapeutics Preclinical Pipeline, 2009 30
Table 9: Insomnia Therapeutics Discovery Pipeline, 2009 30
Table 10: List of Discontinued Drugs for Insomnia, 2009 31
Table 11: GlaxoSmithKline, CNS Marketed Products, 2009 35
Table 12: GlaxoSmithKline, CNS Pipeline Products, 2009 36
Table 13: Sanofi Aventis, CNS Marketed Products, 2009 38
Table 14: Sanofi Aventis, CNS Pipeline Products, 2009 38
Table 15: Somaxon Pharmaceuticals, CNS Pipeline Products, 2009 40
Table 16: Vanda Pharmaceuticals Inc., CNS Pipeline Products, 2009 41
Table 17: Merck, CNS Marketed Products, 2009 42
Table 18: Merck, CNS Pipeline Products, 2009 42

List of Chart


Figure 1: Insomnia Therapeutics Market, Global, Revenue ($bn), 20012009 8
Figure 2: Insomnia Therapeutics Market, Global, Revenue ($bn), 20092017 9
Figure 3: Insomnia Therapeutics Market, Unmet Need, 2009 11
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Insomnia, 2009 13
Figure 5: Insomnia Therapeutics Market, Global, Sales ($m), 2006-2008 14
Figure 6: Insomnia Therapeutics Market, Technology Trends Analytic Framework, 2009 20
Figure 7: Insomnia Therapeutics Market, Technology Trends Analytic Framework, Description, 2009 21
Figure 8: Insomnia Therapeutics Market, Clinical Pipeline by Mechanism of Action (%), 2009 27
Figure 9: Insomnia Therapeutics Market, Pipeline by Phase of Clinical Development (%), 2009 28
Figure 10: Insomnia Therapeutics Market, Implications for Future Market Competition, 2009 33
Figure 11: Insomnia Therapeutics Market, Clinical Pipeline by Company, 2009 34
Figure 12: GlobalData Market Forecasting Model 48

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *